Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 27;17(5):e84904.
doi: 10.7759/cureus.84904. eCollection 2025 May.

Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences

Affiliations
Review

Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences

Suhas Kataveni et al. Cureus. .

Abstract

Clenbuterol is a β2-adrenergic agonist originally developed as a bronchodilator but is now often used without supervision for its perceived muscle-building and fat-burning effects. Although it is not approved for human use in many regions, it continues to be used in bodybuilding and athletics for physique and performance enhancement. Its appeal lies in its ability to influence muscle development and fat metabolism. Many individuals use it due to psychological motivators such as body image concerns and a desire for rapid physical changes. However, its use may result in side effects involving the heart, muscles, and overall physical well-being, such as arrhythmias, hypertension, and muscle spasms. In some cases, it has also been linked to accidental exposure through contaminated food. The widespread misuse of clenbuterol raises ethical concerns in competitive environments. More discussion is needed around developing safer methods of achieving similar goals, and there is a need for increased public awareness and caution regarding its use.

Keywords: anabolic agents; athletes; bodybuilding; clenbuterol; doping; performance-enhancing drugs; β2-adrenergic agonist.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Action of clenbuterol (catabolic and anabolic).
Created by the authors based on data from Dutt et al. [12]. cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; Phospho-AKT, phosphorylated protein kinase B; Ub-proteasome, ubiquitin-proteasome; FoxO3, forkhead box O3 (a transcription factor); MuRF1, muscle RING-finger protein-1 (another E3 ubiquitin ligase)

Similar articles

References

    1. Beta(2) -adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men. Jessen S, Solheim SA, Jacobson GA, Eibye K, Bangsbo J, Nordsborg NB, Hostrup M. Drug Test Anal. 2020;12:610–618. - PubMed
    1. Complete post-mortem investigations in a death involving clenbuterol after long-term abuse. Kintz P, Gheddar L, Ameline A, Dumestre-Toulet V, Verschoore M, Comte J, Raul JS. J Anal Toxicol. 2019;43:660–665. - PubMed
    1. Β-2 agonists as misusing drugs? Assessment of both clenbuterol- and salbutamol-related European Medicines Agency pharmacovigilance database reports. Milano G, Chiappini S, Mattioli F, Martelli A, Schifano F. Basic Clin Pharmacol Toxicol. 2018;123:182–187. - PubMed
    1. Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids - results of an international study. Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schänzer W. Int J Sports Med. 2004;25:124–129. - PubMed
    1. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. JAMA Netw Open. 2018;1:0. - PMC - PubMed

LinkOut - more resources